Italian pharmaceutical company the Menarini Group said on Friday that it has entered into a commercial agreement for Vabomere, Orbactiv and Minocin in 68 Countries with Melinta Therapeutics, a US company.
Menarini will acquire the exclusive rights to commercialise meropenem/vaborbactam (Vabomere] in the US), oritavancin (Orbactiv) and minocycline IV (Minocin IV) in 68 countries in Europe, in Asia-Pacific including China, South Korea, and Australia (Japan excluded) and in the Commonwealth of Independent States (CIS) including Russia, from Melinta Therapeutics.
This agreement reportedly follows Melinta and Menarini's existing commercial and co-development agreement for delafloxacin in the same 68 markets and consolidates Menarini's strategic focus on infectious diseases.
The marketing authorisation application for meropenem/vaborbactam is currently under review by EMA. The Committee for Medicinal Products for Human Use (CHMP) has recommended a marketing authorisation for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia, bacteraemia that occurs in association with any of these infections and infections due to aerobic gram-negative organisms where treatment options are limited.
According to the companies, Orbactiv, a long acting lipoglycopeptide, has been approved by EMA in the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible designated gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).
Minocycline (minocin) is an anti-inflammatory antibiotic sometimes used to mild treat rheumatoid arthritis (RA), concluded the companies.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial